Herein, we report a rare case of primary lung lymphoma in a 61 year-old woman with a history of 6-month nonspecific symptoms like dry cough, fever, chills and weight loss. She was admitted to a hospital and received broadspectrum antibiotics but discharged without full recovery. In her second hospital admission, a bronchoscopic evaluation and transbronchial biopsy were performed, which were not diagnostic. Finally, an open lung biopsy was done. Immunohistochemical (IHC) staining of the specimen suggested pulmonary Hodgkin lymphoma. Because of disease recurrence, a second bronchoscopy was performed and endobronchial biopsy revealed transformation to anaplastic lymphoma. In the second recurrence, we decided to reevaluate the last biopsy specimens in greater details. Finally, after conduction of several staining patterns, the diagnosis of primary composite lymphoma of the lung was made.
INTRODUCTION
Primary lung lymphoma is a rare disease and refers to the proliferation of lymphoid progenitor cells in the airways or the lung parenchyma when there is no extrapulmonary involvement at the time of diagnosis or within 3 months. Extra-nodal non-Hodgkin lymphomas involving the lungs comprise less than 1% of all non-Hodgkin lymphomas (NHL) and 0.5-1% of all primary lung malignancies (1, 2) .
Composite lymphoma is a rare disease that has recently gained attention. It refers to the coexistence of more than one lymphoma in a single organ (3) .
CASE SUMMARIES
A 61 year-old woman presented with dry cough, fever, Gastrointestinal tract, respiratory system, parotid glands, bone and skin may be involved in extra-nodal disease as the common sites (3, 11, 12) . In this case, despite an existing polypoid endobronchial lesion, a pathologic diagnosis was not possible to be made even after taking two bronchoscopic biopsy samples. The disease relapsed after two courses of chemotherapy and it was interesting that it first emerged as an endobronchial lesion in bronchus intermedius. Considering treatment failure, there was a need for re-evaluation of the pathology report and specimens for a curative treatment. A Rituximab-based regimen was curative and the patient has been disease-free so far.
